Variabilität des Therapieansprechens von Gemcitabin bei Pankreaskarzinom: Identifizierung relevanter Genpolymorphismen

Retrospektive Studie bei Patienten mit Pankreaskarzinom

Variability of therapy response in gemcitabine treated pancreatic carcinoma: Identifying relevant gene polymorphisms

Retrospectiv study in patients with pancreatic carcinoma

by Alexander Schaudinn
Doctoral thesis
Date of Examination:2013-01-28
Date of issue:2013-01-23
Advisor:Prof. Dr. Jürgen Brockmöller
Referee:Prof. Dr. Jürgen Brockmöller
Referee:PD Dr. Torsten Liersch
Persistent Address: http://dx.doi.org/10.53846/goediss-3369

 

 

Files in this item

Name:Dissertation A.Schaudinn 21.01.2013 Final.pdf
Size:2.90Mb
Format:PDF
Description:Dissertation PDF
Name:Dissertation A.Schaudinn 21.01.2013 Final.docx
Size:3.11Mb
Format:VND.OPENXMLFORMATS-OFFICEDOCUMENT.WORDPROCESSINGML.DOCUMENT
Description:Dissertation WORD

The following license files are associated with this item:

Abstract

English

Gene polymophisms could play an important role in the variability of therapy response in gemcitabine treated patients with pancreatic carcinoma. The retrospective study showed that a polymorphism in ENT-1, a carrier of gemcitabine, had an influence on overall survival.
Keywords: Gemcitabine; Gene Polymorphism; ENT1; Pancreatic Carcinoma
 
Statistik